Filing Analysis
Psychemedics Corporation completed a stock purchase agreement with 3K Limited Partnership to fund the settlement of fractional shares from a recent reverse stock split and provide $500,000 in working capital. The company subsequently repurchased a portion of these shares on December 10, 2024.
🚩 Red Flags
- Transaction directly linked to a recent reverse stock split (often indicative of liquidity or compliance issues).
- The need for an external partner to fund the settlement of fractional shares suggests potential cash flow constraints.
📋 Key Facts
- 3K Limited Partnership purchased 1,409,712 shares at $2.35 per share on December 3, 2024.
- The transaction was structured to fund the purchase of fractional share interests resulting from a recent reverse stock split.
- The deal included an additional $500,000 provided by 3K for working capital and general corporate purposes.
- On December 10, 2024, the Company repurchased 320,708 shares from 3K at $2.35 per share.
Psychemedics Corporation has announced its intent to voluntarily withdraw from the Nasdaq Capital Market and deregister its common stock. This follows a complex 1-for-5,000 reverse split combined with a 5,000-for-1 forward split designed to cash out small shareholders.
🚩 Red Flags
- Voluntary delisting/withdrawal from Nasdaq (Item 3.01).
- Intent to deregister under Section 12(b) and cease public reporting (Form 15).
- Extreme reverse stock split (1-for-5,000) used as a mechanism for a cash-out of minority shareholders.
- The 'Stock Split' structure effectively forces out small retail investors with $2.35 per share.
📋 Key Facts
- Company provided advance notice to Nasdaq of intent to voluntarily withdraw from listing on December 3, 2024.
- The Company intends to file Form 25 and Form 15 to cease reporting as a public company.
- A 1-for-5,000 reverse stock split was implemented effective Dec 3, 2024, at 5:01 p.m. ET.
- A 5,000-for-1 forward stock split followed immediately to reconvert shares for large holders.
- Stockholders owning fewer than 5,000 shares prior to the reverse split will receive $2.35 per share in cash and will no longer be stockholders.
Psychemedics Corporation announced the results of its annual meeting where stockholders approved a significant reverse stock split (ratio between 1-for-4,000 and 1-for-6,000) and a subsequent forward stock split. The filing also includes the ratification of director elections and an executive compensation advisory vote.
🚩 Red Flags
- Extreme reverse stock split ratio (up to 1-for-6,000) typically indicates severe share price erosion or a desperate attempt to maintain NASDAQ compliance.
- The complexity of the proposed splits (reverse followed by forward) suggests highly non-standard capital restructuring.
- Ratification of a Stock Purchase Agreement involving an insider/director (Peter H. Kamin) and his trusts/foundations indicates significant related-party transactions.
📋 Key Facts
- Stockholders approved a reverse stock split with a ratio between 1-for-4,000 and 1-for-6,000.
- Stockholders approved a subsequent forward stock split with a ratio between 4,000-for-1 and 6,000-for-1.
- Five directors (Robyn C. Davis, Brian Hullinger, Peter H. Kamin, Darius G. Nevin, Andrew M. Reynolds) were re-elected to the Board.
- Advisory vote on executive compensation was approved.
- Whitley Penn LLP was ratified as the independent registered public accounting firm for the year ending Dec 31, 2024.
- Stockholders ratified a Stock Purchase Agreement dated August 12, 2024, involving Peter H. Kamin and related entities.
Psychemedics Corporation announced its financial results for the third quarter ending September 30, 2024. The filing serves as a formal announcement of the quarterly earnings release.
📋 Key Facts
- Reporting period: Third Quarter ending September 30, 2024
- Filing date: November 12, 2024
- The company issued a press release (Exhibit 99.1) containing the results of operations and financial condition.
Psychemedics Corporation filed an 8-K to announce its financial results for the second quarter ended June 30, 2024. The filing serves as a formal notification of the release of quarterly earnings data.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Second Quarter ending June 30, 2024
- The company issued a press release (Exhibit 99.1) containing the results of operations and financial condition.
- Signed by Brian Hullinger, President and CEO.
Psychemedics Corporation has announced a plan to execute a massive reverse stock split (1-for-4,000 to 1-for-6,000) as part of a 'going private' transaction. This move is intended to facilitate the termination of its public company reporting obligations and delisting from the Nasdaq Capital Market.
🚩 Red Flags
- Extreme reverse stock split ratio (up to 1-for-6,000), typically indicative of severe distress or restructuring.
- Intent to delist from Nasdaq and cease SEC reporting obligations.
- The transaction is characterized as a 'going private' transaction under Rule 13e-3.
- Significant dilution/restructuring involving the cash-out of minority shareholders.
📋 Key Facts
- The company entered into a stock purchase agreement with 3K Limited Partnership and Peter H. Kamin for up to $3,750,000 at $2.35 per share.
- A proposed reverse stock split ratio between 1-for-4,000 and 1-for-6,000 is planned.
- The transaction includes a 'cash-out' provision where stockholders with fewer shares than the denominator will receive $2.35 per share in cash.
- The company intends to delist from Nasdaq and terminate its SEC reporting obligations (going private).
- Approximately 1.2 million shares (roughly 21% of outstanding stock) are estimated to be cashed out at a mid-point ratio.
Psychemedics Corporation has dismissed its independent registered public accounting firm, BDO USA, P.C., and appointed Whitley Penn LLP as its new auditor.
🚩 Red Flags
- Auditor change (dismissal of a major firm like BDO) can sometimes precede restatements or internal control issues, though the company explicitly denies disagreements in this filing.
📋 Key Facts
- BDO USA, P.C. was dismissed by the Audit Committee on June 6, 2024.
- Whitley Penn LLP was engaged as the new independent registered public accounting firm on June 12, 2024.
- The company stated there were no disagreements with BDO regarding accounting principles, practices, financial statement disclosure, or auditing scope/procedures.
- Audit reports for fiscal years ended December 31, 2023, and December 31, 2022, contained no adverse opinions or disclaimers.
Psychemedics Corporation entered into a Lease Termination Agreement to exit its Culver City, CA facility. The termination is effective June 30, 2024.
🚩 Red Flags
- Cash outflow of $110,000 to exit an existing obligation.
📋 Key Facts
- Termination of lease for premises at 5750 Hannum Avenue, Culver City, CA 90230.
- Effective date of lease termination: June 30, 2024.
- The Company will pay approximately $110,000 to the Landlord (Culver City/Hannum, LLC) for the early termination.
- Company expects a net cost saving of approximately $250,000 over the remaining original lease term.
Psychemedics Corporation filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notice that a press release containing these results was issued on May 14, 2024.
📋 Key Facts
- Report date: May 14, 2024
- Reporting period: First quarter ended March 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
- Company is listed on NASDAQ under the symbol PMD.
Psychemedics Corporation filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing primarily serves as a placeholder to incorporate a press release containing the company's annual performance data.
📋 Key Facts
- The filing reports on the period ending December 31, 2023.
- Financial results were announced via a press release dated March 28, 2024.
- The report was signed by Daniella Mehalik, Vice President of Finance.
Psychemedics Corporation announced that its Compensation Committee approved 2024 cash performance bonus plans for the CEO and other executive officers. These plans are tied to corporate financial targets and individual performance goals.
📋 Key Facts
- CEO Brian Hullinger's 2024 cash bonus plan has a target of $190,000 and a maximum of $285,000.
- Other executive officers are eligible for bonuses ranging from 25% to 40% of their base salary.
- Bonus payouts are contingent upon achieving specific corporate financial performance targets and individual goals.
- The CEO will assess other participants' performance at the end of fiscal year 2024.